KALV
KalVista Pharmaceuticals, Inc.
$27.00
+0.00
(+0.00%)
Mkt Cap
1.44B
Volume
4,262,878
52W Range
9.83-27
Sector
Healthcare
Beta
-0.29
EPS (TTM)
-3.23
P/E Ratio
-5.00
Revenue (TTM)
73.62M
Rev Growth (5Y)
+36.4%
EPS Growth (5Y)
N/A
Company Description
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 73.62M | 0 | 0 | 0 | 0 | 0 | 12.69M | 16.13M | 8.39M | 1.50M | 2.13M | 1.80M |
| Net Income | (164.29M) | (183.44M) | (126.64M) | (92.91M) | (82.34M) | (46.24M) | (29.12M) | (20.82M) | (15.80M) | (18.60M) | (11.44M) | (7.23M) |
| EPS | -3.23 | -3.69 | -3.44 | -3.33 | -3.36 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 |
| Free Cash Flow | (83.33M) | (153.34M) | (89.67M) | (76.46M) | (79.06M) | (30.25M) | (45.04M) | (37.45M) | 9.13M | (23.80M) | (13.17M) | (6.49M) |
| FCF / Share | -1.64 | -3.09 | -2.44 | -2.74 | -3.23 | -1.58 | -2.54 | -2.48 | 0.88 | -2.45 | -2.76 | -5.55 |
| Operating CF | (81.62M) | (152.91M) | (89.23M) | (75.26M) | (78.13M) | (30.17M) | (44.82M) | (36.37M) | 10.56M | (23.72M) | (13.16M) | (6.37M) |
| Total Assets | 335.38M | 250.77M | 235.40M | 183.20M | 203.88M | 272.01M | 92.53M | 118.13M | 61.39M | 34.34M | 24.75M | 6.64M |
| Total Debt | 151.57M | 6.31M | 7.32M | 8.23M | 8.19M | 5.91M | 1.65M | 54,000 | 279,000 | 0 | 4.61M | 6.57M |
| Cash & Equiv | 229.34M | 98.64M | 31.79M | 56.24M | 30.73M | 50.59M | 15.79M | 32.01M | 51.05M | 30.95M | 21.76M | 3.90M |
| Book Value | (2.71M) | 95.39M | 206.58M | 161.03M | 185.09M | 257.19M | 83.75M | 96.74M | 27.25M | 31.33M | 21.50M | (44.18M) |
| Return on Equity | N/A | -1.92 | -0.61 | -0.58 | -0.44 | -0.18 | -0.35 | -0.22 | -0.58 | -0.59 | -0.53 | N/A |
| Metric | Q3 2026 | Q4 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.92M | 40.86M | 13.69M | 1.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (5.37M) | (23.49M) | (49.48M) | (60.10M) | (52.23M) | (48.51M) | (42.27M) | (40.44M) | (44.65M) | (29.03M) | (27.65M) | (25.32M) |
| EPS | -0.11 | -1.08 | -0.92 | -1.12 | -1.05 | -0.92 | -0.91 | -0.87 | -1.02 | -0.84 | -0.80 | -0.74 |
| Free Cash Flow | 45.52M | (14.58M) | N/A | (54.79M) | (40.01M) | (32.81M) | (39.75M) | (40.24M) | (15.23M) | (27.59M) | (19.83M) | (26.74M) |
| FCF / Share | 0.90 | -0.29 | N/A | -1.02 | -0.81 | -0.62 | -0.85 | -0.87 | -0.35 | -0.79 | -0.57 | -0.78 |
| Operating CF | 45.36M | (14.46M) | N/A | (54.50M) | (40.36M) | (32.68M) | (39.64M) | (40.22M) | (15.11M) | (27.57M) | (19.82M) | (26.73M) |
| Total Assets | 335.38M | 335.38M | N/A | 215.50M | 250.77M | 275.99M | 160.83M | 200.20M | 235.40M | 113.97M | 138.74M | 160.33M |
| Total Debt | 284.21M | 151.57M | N/A | 6.14M | 6.31M | 5.78M | 6.21M | 6.25M | 7.32M | 7.44M | 7.69M | 7.99M |
| Cash & Equiv | 229.34M | 229.34M | N/A | 124.30M | 98.64M | 167.29M | 41.58M | 31.85M | 31.79M | 23.06M | 57.67M | 49.41M |
| Book Value | (2.71M) | (2.71M) | N/A | 40.79M | 95.39M | 145.13M | 133.99M | 172.80M | 206.58M | 88.58M | 114.45M | 139.34M |
| Return on Equity | N/A | N/A | N/A | -1.47 | -0.55 | -0.33 | -0.32 | -0.23 | -0.22 | -0.33 | -0.24 | -0.18 |
KALV News
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders